Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Bilcare Limited (526853) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Bilcare Limited ₹17.35, price ₹96.70, upside -82.1%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
BL
Thin data
Oct 3, 2026
Bilcare Limited
526853 · BSEStretched ValuationStrong overvaluation with only moderate quality.
Solidly profitable · 13.6% net margin (TTM)
Generates free cash flow
Quality 59/100
Fair value ₹17.35 · Strongly overvalued (−82.1%)
Weak Growth (revenue 5y +3.3 %/yr in INR)
High debt
Trails peers (2/10)
Narrow moat 34/100
Thin data
Structural break
Watch Bilcare Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹32.10 – ₹113.60 · fair‑value band ₹11.14 – ₹24.25 · the ₹96.70 price screens above the ₹17.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Bilcare in your weekly email
Every Wednesday you see whether Bilcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Bilcare Limited provides pharmaceutical packaging research solutions and global clinical services in India and internationally.
Show more
Bilcare Limited provides pharmaceutical packaging research solutions and global clinical services in India and internationally. The company offers various specialty polymer films and aluminum foils primarily used for packaging solid dosage pharmaceutical products; and other packaging films solutions for applications in ID card, specialty film, and food packaging industries. It also provides clinical trial materials supplies and project management services; and nonClonableID, an anti-counterfeiting, security, and brand protection solution for various industry sectors. The company serves pharmaceutical and biotechnology industries. Bilcare Limited was incorporated in 1987 and is based in Pune, India.
Stock analysis
Bilcare Limited (526853) currently trades at ₹96.70, while our model-based Fair Value estimate is ₹17.35, 82.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹55.98 per share, and 10 of the 17 models we run sit above the ₹96.70 price.
Bear case: the Earnings-Based group reads lowest at ₹6.07, and 7 of the 17 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹11.14 (bear) to ₹24.25 (bull), the price of ₹96.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Bilcare Limited reported revenue of ₹7.3B in FY2026 versus ₹8.4B in FY2022, a compound −3.5%/yr. Reported net income was ₹17.2M in FY2026.
Key figures
Market cap ₹1.1B (≈ $11.3M) · P/S ratio 0.15 · EPS (TTM) ₹41.68 · Net margin 0.2% · Return on assets (EBIT) 4.1% · Operating margin 1.0% · Revenue (TTM) ₹7.2B · Revenue growth (YoY) −76.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 14% below its 52-week high and 86% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Materials peers we cover trades at −22% fair-value upside, at −82%, 526853 screens richer than that median.
Fair Value models
Bear ₹11.14
Fair Value ₹17.35
Bull ₹24.25
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹21.24 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
₹527.01
₹788.97
₹1,259
79
Growth DCF
₹557.31
₹809.70
₹1,228
78
5Y EBITDA Exit
₹169.53
₹242.32
₹339.02
75
All 18 models by family
DCF Models
FCF DCF
₹527.01
₹788.97
₹1,259
79
Owner Earnings
₹108.86
₹217.85
₹413.42
72
5Y Revenue Exit
₹149.31
₹207.32
₹289.69
73
5Y EBITDA Exit
₹169.53
₹242.32
₹339.02
75
5Y P/E Exit
₹101.54
₹124.63
₹155.06
72
10Y Revenue Exit
₹295.14
₹351.46
₹402.69
68
10Y EBITDA Exit
₹309.54
₹372.61
₹430.99
70
10Y P/E Exit
₹269.19
₹301.48
₹325.46
65
Earnings-Based
Graham-Dodd
₹4.97
₹6.07
₹6.83
67
Multiples
P/E Multiple
₹9.31
₹12.42
₹15.52
63
P/S Multiple
₹9.31
₹12.42
₹15.52
58
P/B Multiple
₹9.31
₹12.42
₹15.52
55
EV/EBITDA
n/a
n/a
₹46.83
62
Asset-Based
NCAV (Graham)
₹41.78
₹55.98
₹83.55
54
Growth DCF
Growth DCF
₹557.31
₹809.70
₹1,228
78
Rev-Margin DCF
₹149.31
₹224.66
₹327.21
72
Economic Profit
Residual Income
₹56.53
₹53.27
₹51.19
71
Growth Earnings
Growth-Adj P/E
₹6.64
₹9.48
₹12.32
67
Notify me when 526853 reaches fair value
Put 526853 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
59/100
Of which business quality 55 · Market factors (momentum, volatility) 67
Profitability
33
Margins and returns on capital today
Quality Growth
60
Are margins and returns improving?
Cashflow
82
Earnings quality: real cash, not paper profit
Fin. Strength
6
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
14
Calm price path (market factor)
Momentum
93
Price trend over the last 3–12 months (market factor)
52W Momentum
82
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−6.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Start year 2021 (pandemic). Over 10 years: −12.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−51.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−51.5%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 3%
⚠ Revenue per share shrinking 14.8%/yr over ~8Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
526853 screens overvalued: fair value 82% below the price. Compare with Daelim Paper Co →
Compare Bilcare Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Containers & Packaging” was too small, so the broader sector is used.)Materials · 3243 stocks
Beats the sector median on 2/9 measures
Overall it trails its sector peers.
Valuation Multiplesvs Materials median · lower = cheaper
Context: sector, industry, market
- Is the Materials sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Containers & Packaging stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Daelim Paper Co 017650 | 10,800 KRW | 2,977 KRW | −72% |
| M2N Co 033310 | 1,468 KRW | 753.29 KRW | −49% |
| RDBRL RDBRL | ₹162.10 | ₹104.53 | −36% |
| ECOPLAST ECOPLAST | ₹470.10 | ₹455.29 | −3% |
| HINDTIN HINDTIN | ₹110.10 | ₹159.89 | +45% |
| GUJCONT GUJCONT | ₹170.05 | ₹132.68 | −22% |
| DUROPACK DUROPACK | ₹59.85 | ₹59.59 | +0% |
| SARTHAKIND SARTHAKIND | ₹24.02 | ₹63.67 | +165% |
| KIRANPR KIRANPR | ₹24.80 | ₹3.20 | −87% |
| RCCL RCCL | ₹30.00 | ₹9.15 | −70% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Bilcare Limited (526853) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹17.35 versus a price of ₹96.70, about −82% upside (overvalued).
What is the fair value of 526853?
Our model-based fair value for Bilcare Limited is ₹17.35 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹96.70.
What is the quality score of 526853?
Bilcare Limited has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bilcare Limited (526853)?
Our model-based price target is the fair value of ₹17.35 (as of Oct 3, 2026) from 18 valuation models. Cautious scenario ₹11.14, optimistic scenario ₹24.25. It is a calculation from audited fundamentals, not an analyst target.
What is the Bilcare Limited stock forecast for 2026?
Our models put fair value at ₹17.35, about −82% upside versus a price of ₹96.70 (overvalued). Cautious scenario ₹11.14, optimistic scenario ₹24.25. The calculation is refreshed regularly with new filings.
What is the revenue of Bilcare Limited (526853)?
Bilcare Limited reported trailing-twelve-month revenue of about ₹7.2B (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Bilcare Limited (526853)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bilcare Limited it is ₹17.35 per share (as of Oct 3, 2026), against a price of ₹96.70. It is the blended result of 18 valuation models (cash flow, earnings, asset, dividend).
Is Bilcare Limited stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 526853 trades above its calculated fair value: price ₹96.70, fair value ₹17.35, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 526853?
No. The price is what the market pays today (₹96.70); the fair value is what the company's own numbers justify (₹17.35). For Bilcare Limited the two are ₹79.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bilcare Limited worth?
The market values Bilcare Limited at about ₹1.1B (market capitalisation, as of Oct 3, 2026). Per share that is ₹96.70; our models calculate a fair value of ₹17.35 per share.
What do the bullish and bearish scenarios say about 526853?
Our models span a range for Bilcare Limited: cautious scenario ₹11.14, base ₹17.35, optimistic ₹24.25 per share (as of Oct 3, 2026, price ₹96.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bilcare Limited (526853)?
Balance-sheet figures for Bilcare Limited (as of Oct 3, 2026): debt of 2.29 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 526853 from its 52-week high?
Bilcare Limited trades at ₹96.70, about 14% below its 52-week high of ₹112.45 and 86% above the low of ₹51.94 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹17.35 is for.
Which stocks are comparable to Bilcare Limited?
From the same area (Materials) we also value Daelim Paper Co, M2N Co, RDBRL, ECOPLAST, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bilcare Limited stock attractive at the current price?
The data as of Oct 3, 2026: price ₹96.70, calculated fair value ₹17.35 (−82%), Quality Score 59/100, from 18 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 526853 calculated?
We run Bilcare Limited through 18 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹17.35, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Bilcare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bilcare Limited (526853)?
The closing price on Oct 1, 2026 was ₹96.70. Our model-based fair value is ₹17.35, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bilcare Limited right now?
The price sits above even our optimistic bull case (₹24.25). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹11.14 to ₹24.25) leaves room in how you read the outcome.
Key figures of Bilcare Limited
How large is the market capitalisation of Bilcare Limited (526853)?
The market capitalisation of Bilcare Limited is ₹1.1B (≈ $11.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bilcare Limited (526853)?
The price-to-sales ratio of Bilcare Limited is 0.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bilcare Limited (526853)?
Earnings per share at Bilcare Limited are ₹41.68. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bilcare Limited (526853)?
The net margin of Bilcare Limited is 0.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Bilcare Limited (526853)?
On an EBIT basis the return on assets of Bilcare Limited is 4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bilcare Limited (526853)?
The operating margin of Bilcare Limited is 1.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bilcare Limited (526853)?
Revenue at Bilcare Limited is growing −76.9% versus a year earlier (3y avg −9.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Bilcare Limited (526853) generate?
The free cash flow of Bilcare Limited is ₹1.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bilcare Limited (526853) carry?
The net debt of Bilcare Limited is ₹6.0B (fiscal year 2026, ≈ 5.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bilcare Limited in the live analysis
One click puts Bilcare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.